NCT00525499 is a Phase 2 clinical trial of ASC-J9 cream in Acne Vulgaris, sponsored by AndroScience Corp.

Who is sponsoring NCT00525499?

NCT00525499 is sponsored by AndroScience Corp.

What drugs are being tested in NCT00525499?

Interventions in NCT00525499: ASC-J9 cream, placebo.

What condition does NCT00525499 study?

NCT00525499 studies Acne Vulgaris.

Is NCT00525499 still recruiting?

NCT00525499 is currently completed. Last updated 16 November 2011.

Are results published for NCT00525499?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-11-16 · How we verify

NCT00525499

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Dose-Ranging Clinical Study to Evaluate the Safety and Efficacy of ASC-J9 Cream Applied Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris

Completed Phase 2 Results posted Last updated 16 November 2011

What this trial tests

Phase 2 trial testing ASC-J9 cream in Acne Vulgaris in 186 participants. Completed in 1 July 2008.

Timeline

1 August 2007

Primary endpoint
1 April 2008

1 July 2008

Quick facts

Lead sponsor	AndroScience Corp
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	186
Start date	1 August 2007
Primary completion	1 April 2008
Estimated completion	1 July 2008
Sites	10 locations across United States

Drugs / interventions tested

ASC-J9 cream — full drug profile →
placebo

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

AndroScience Corp — full company profile →

Who can join

12 and older, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12
Time frame: Baseline to Week 12
Percent change in inflammatory lesion counts from Baseline to Week 12. It is calculated by taking the Week 12 count minus the Baseline count and then dividing by the Baseline count. Thus, a negative percent change will reflect a reduction in lesion counts.

Sponsor's own description

The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.
Kim MJ, Jeon JH. · · 2022 · cited 60× · PMID 35269986 · DOI 10.3390/ijms23052846
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.
Chen QH, Munoz E, Ashong D. · · 2024 · cited 36× · PMID 38339414 · DOI 10.3390/cancers16030663
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective.
Huang J, Lin B, Li B. · · 2022 · cited 35× · PMID 35372068 · DOI 10.3389/fonc.2022.865350

Verify or expand the search:

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00525499 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AndroScience Corp
Last refreshed: 16 November 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00525499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing